Source:http://linkedlifedata.com/resource/pubmed/id/20105224
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2010-11-2
|
| pubmed:abstractText |
The serodiagnostics of extracellular domain (ECD) HER-2/neu has turned into an evidenced-based tumour marker for HER-2/neu-positive breast cancer patients. This study investigated the clinical relevance of immunohistochemical and serum HER-2/neu in 44 patients with advanced ovarian cancer. The Hercept-Test® from DAKO Diagnostics was used to analyse immunohistochemical HER-2/neu expression. The HER-2/neu ECD in serum was determined quantitatively by Bayer Immuno 1™ Immunoanalyser. The HER-2/neu serum values were correlated to the clinical course of disease and to established prognostic factors, i.e. progression-free and overall survival. Some 23% of patients (n = 11) expressed HER-2/neu serum levels higher than 15 ng/mL, whereas only 7.7% (n = 2) of the patients examined by immunohistochemistry showed a HER-2/neu overexpression of the tissue. None of them revealed an overexpression of HER-2/neu ECD by serodiagnostics. HER-2/neu overexpression did not correlate significantly to any of the analysed prognostic factors. According to progression-free and overall survival, there was no significant difference between serologically HER-2/neu-positive or negative patients. For ovarian cancer patients, neither high HER-2/neu serum levels, nor immunohistochemically determined HER-2/neu positivity, appear to predict the course of disease. This study shows a lack of association between the immunohistochemical HER-2/neu status and the serum level of solute extracelluar HER-2/neu domain.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
N
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1365-2354
|
| pubmed:author | |
| pubmed:copyrightInfo |
© 2010 Blackwell Publishing Ltd.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
809-15
|
| pubmed:meshHeading |
pubmed-meshheading:20105224-Adult,
pubmed-meshheading:20105224-Aged,
pubmed-meshheading:20105224-Disease Progression,
pubmed-meshheading:20105224-Female,
pubmed-meshheading:20105224-Humans,
pubmed-meshheading:20105224-Immunohistochemistry,
pubmed-meshheading:20105224-Middle Aged,
pubmed-meshheading:20105224-Ovarian Neoplasms,
pubmed-meshheading:20105224-Prognosis,
pubmed-meshheading:20105224-Receptor, erbB-2,
pubmed-meshheading:20105224-Survival Analysis,
pubmed-meshheading:20105224-Tumor Markers, Biological
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients.
|
| pubmed:affiliation |
Department of Obstetrics and Gynaecology, University Hospital of Cologne, Cologne, Germany.
|
| pubmed:publicationType |
Journal Article
|